ClinicalTrials.gg

Program

luxdegalutamide

A development code. Also written as “JSB462”.

In Novartis's pipeline, Androgen receptor protein degrader. Its studies are mostly in Prostatic Neoplasms · Prostatic Neoplasms, Castration-Resistant, led by Novartis.

Furthest: phase 2, since May 8, 20253 company-led studies, 3 open or runningNext primary completion: Dec 3, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis33 open or runningphase 2since May 8, 2025May 8, 2025Dec 3, 2026phase 2 · NCT06991556
  • Named in Novartis’s own pipeline as JSB462 (luxdegalutamide), phase 2, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 8, 2025First studies: 2 phase 2 studiesFirst studyNCT06991556, NCT07047118
  2. Sep 8, 2025Phase 1 study in Prostatic NeoplasmsNCT07174063 · 6 enrolled · Japan

Ahead

  1. Dec 3, 2026Primary completion: phase 2 study in Metastatic Hormone-sensitive Prostate CancerNCT06991556
  2. Jan 29, 2027Primary completion: phase 1 study in Prostatic NeoplasmsNCT07174063
  3. Jul 16, 2027Primary completion: phase 2 study in Prostatic Neoplasms, Castration-ResistantNCT07047118

TargetBeta

“Androgen receptor protein degrader”the company's pipeline, read by Claude · source

Other programs on AR

ProgramCompanyFurthest phaseStudies
enzalutamideruleAstellas Pharmaphase 469
apalutamideruleJohnson & Johnsonphase 431
darolutamideruleBayerphase 426
Clascoteronerulecassiopea-spaphase 419
ostarinerulegtxphase 315
rezvilutamideruleJiangsu HengRui Medicinephase 313
dezandrodegruleBristol-Myers Squibbphase 35
Cyproterone AcetateruleEurofarma Laboratoriosphase 34
Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915Johnson & Johnsonphase 33
HRS-5041Jiangsu HengRui Medicinephase 26
luxdegalutamideNovartisphase 22
Androgen Receptor Degrader AZD9750ruleAstraZenecaphase 21

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07174063Prostatic Neoplasms · Japan1Active, not recruitingJan 29, 20276
NCT07047118Prostatic Neoplasms, Castration-Resistant · United States, Australia, Austria and more2Active, not recruitingJul 16, 2027138
NCT06991556Metastatic Hormone-sensitive Prostate Cancer · United States, Australia, Brazil and more2Active, not recruitingDec 3, 2026168

How it is read

Names in the registry

  • “JSB462”, 3 entries

Codes read as this program: JSB462.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.